More Leaks in the Dam: Who's the New Whistleblower on Avandia?
This article was originally published in RPM Report
Executive Summary
The Senate Finance Committee loves FDA whistleblowers. And it sounds like they have found another one as part of their investigation of the review of GlaxoSmithKline PLC’s diabetes drug rosiglitazone (Avandia).